Fremont, CA, United States of America

Dong Fang Shi

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 8.8

ph-index = 4

Forward Citations = 33(Granted Patents)


Company Filing History:


Years Active: 2012-2014

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovator Dong Fang Shi: Pioneering Advances in Metabolic Disease Therapies

Introduction

Dong Fang Shi, a distinguished inventor based in Fremont, CA, has made significant contributions to the field of medicine with a focus on metabolic diseases. With a total of six patents to his name, his innovative work is aimed at improving treatment options for conditions like Type II diabetes.

Latest Patents

Among his latest patents is the development of N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders. This patent outlines compounds and methods that target Type II diabetes and other diseases associated with poor glycemic control. Another noteworthy patent covers GPR120 receptor agonists and their uses, which also extends their therapeutic potential to treat metabolic diseases, including Type II diabetes.

Career Highlights

Dong Fang Shi has been instrumental in advancing research and development at leading companies such as Metabolex, Inc. and Cymabay Therapeutics, Inc. Throughout his career, he has been devoted to exploring new therapeutic pathways to address metabolic health challenges.

Collaborations

In his journey as an innovator, Dong has collaborated with esteemed colleagues such as Jiangao Song and Jingyuan Ma. These partnerships have significantly enhanced the quality and scope of his research and patent contributions.

Conclusion

Dong Fang Shi's innovative spirit and dedication to advancing treatments for metabolic disorders have earned him recognition in the field. With multiple patents focusing on critical therapeutic approaches, he continues to be a valuable asset to the scientific community, aiming to improve the lives of many affected by diabetes and related conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…